RecruitingPhase 2NCT04930653

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

A Phase II Study of Combination Extracorporeal Photopheresis (ECP) and Mogamulizumab in Erythrodermic CTCL

Sponsor

City of Hope Medical Center

Enrollment

34 participants

Start Date

Oct 19, 2022

Study Type

INTERVENTIONAL

Conditions

Primary Cutaneous T-Cell Non-Hodgkin Lymphoma Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8 Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8 Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8 Sezary Syndrome Folliculotropic Mycosis Fungoides Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8 Transformed Mycosis Fungoides

Summary

This phase II trial studies the effect of extracorporeal photopheresis (ECP) and mogamulizumab in treating patients with erythrodermic cutaneous T cell lymphoma (CTCL), a type of skin lymphoma. CTCL is a rare type of cancer that begins in the white blood cells called T cells. Erythrodermic is a widespread red rash that may cover most of the body. ECP is a medical treatment that removes blood with a machine, isolates white blood cells and exposes them to ultra violet light, then returns the cells to the body. Mogamulizumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving mogamulizumab with ECP may work together to kill the tumor cells directly (with mogamulizumab) and boost immune response to cancer (with ECP).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests a combination of two treatments — extracorporeal photopheresis (a procedure that treats blood cells with light outside the body) and a drug called mogamulizumab — for people with an aggressive skin lymphoma called cutaneous T-cell lymphoma. **You may be eligible if...** - You are 18 or older - You have been diagnosed with mycosis fungoides or Sézary syndrome (types of skin lymphoma) - Your disease is at stage IB or higher - You are in reasonably good physical condition (ECOG score of 2 or less) **You may NOT be eligible if...** - Your disease is at an earlier stage than specified - You are not physically well enough to participate - You are pregnant or breastfeeding - You do not agree to provide tumor tissue samples Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREExtracorporeal Photopheresis

Undergo ECP

BIOLOGICALMogamulizumab

Given IV

OTHERQuality-of-Life Assessment

Ancillary studies

OTHERQuestionnaire Administration

Ancillary studies

Locations(3)

Mayo Clinic

Scottsdale, Arizona, United States

City of Hope Medical Center

Duarte, California, United States

Winship Cancer Institute of Emory University

Atlanta, Georgia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04930653

Related Trials

Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance

NCT071325676 locations

A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab

NCT0700310010 locations